查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
病毒疫苗细胞培养基市场：按细胞培养类型、培养基类型、运营规模
市场调查报告书
商品编码
1064938

病毒疫苗细胞培养基市场：按细胞培养类型、培养基类型、运营规模

Viral Vaccine Cell Culture Media Market Distribution by Type of Cell Culture (Adherent and Suspension), Type of Media (Animal Component Free, Protein Free and Serum Free), Scale of Operation (Clinical Operations and Commercial Operations),
出版日期: | 出版商: Roots Analysis | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

洞察示例

近年来，针对各种疾病的先进疫苗已获得各监管机构的批准。在 COVID-19 出现后，对病毒疫苗的需求猛增。随着对病毒疫苗的需求稳步增长，预计病毒疫苗细胞培养基市场将在未来十年稳步增长。

本报告调查了全球病毒疫苗细胞培养基市场，并提供了市场概况，以及按细胞培养类型、培养基类型、运营规模和进入市场的公司概况划分的市场规模。

目录

第一章前言

第2章执行摘要

第三章介绍

  • 章节概述
  • 病毒疫苗介绍
  • 病毒疫苗的种类
  • 细胞培养类型
  • 细胞培养基的种类
  • 细胞培养基的优势
  • 与细胞培养基相关的限制
  • 结论

第四章市场情况

  • 章节概述
  • 病毒疫苗细胞培养基：市场整体情况
  • 病毒疫苗细胞培养基开发商：市场情况

第 5 章公司简介

  • 章节概述
  • 北美参与企业
    • Creative Biolabs
    • Jianshun Biosciences
    • Thermo Fisher Scientific
  • 欧洲参与企业
    • Merck
    • Sartorius
    • Xell
  • 亚太地区参与企业
    • ATZ labs
    • OPM Biosciences

第 6 章最近的发展和举措

  • 章节概述
  • 合作模式
  • 病毒疫苗细胞培养基：近期的合作伙伴和合作
  • 病毒疫苗细胞培养基：近期扩展

第7章潜在合作伙伴分析

  • 章节概述
  • 范围及调查方法
  • 病毒疫苗细胞培养基开发商的潜在战略合作伙伴

第8章产品竞争力分析

第九章品牌定位

第10章专利分析

  • 章节概述
  • 范围及调查方法
  • 病毒疫苗细胞培养基：专利解析
  • 病毒疫苗细胞培养基：专利基准分析
  • 病毒疫苗细胞培养基：专利评价分析

第11章需求分析

  • 章节概述
  • 范围及调查方法
  • 全球对病毒疫苗的需求

第12章市场预测

  • 章节概述
  • 预测性调查方法和关键假设
  • 2022-2035年全球病毒疫苗细胞培养基市场
  • 病毒疫苗细胞培养基市场：按细胞培养类型分析，2022-2035
  • 2022-2035年病毒疫苗细胞培养基市场：按培养基类型分析
  • 病毒疫苗细胞培养基市场：按运营规模分析，2022-2035
  • 病毒疫苗细胞培养基市场：2022-2035 年最终用户类型分析
  • 病毒疫苗细胞培养基市场：区域分析，2022-2035

第13章结论

第14章采访记录

第15章附录一：聚合数据

第16章附录二：公司和组织名单

Title:
Viral Vaccine Cell Culture Media Market Distribution
by Type of Cell Culture (Adherent and Suspension), Type of Media (Animal Component Free, Protein Free and Serum Free), Scale of Operation (Clinical Operations and Commercial Operations), Type of End-User (Industry Players and Non-Industry Players), and Key Geographical Regions (North America, Europe, Asia-Pacific, and Rest of the World): Industry Trends and Global Forecasts, 2022-2035.

Example Insights:

Overview

Over the past few years, a number of advanced vaccines targeting a myriad of disease indications have received approval from various regulatory authorities. Post the onset of COVID-19, there has been a surge in the demand for viral vaccines. In fact, it is estimated that more than 4.5 billion people, across the globe, have received at least a single dose of COVID-19 vaccine. In other words, around 60% of the global population has been vaccinated against COVID-19. However, as the global population continues to rise, the demand for such vaccines is likely to be there in the foreseen future as well. Taking into consideration the prevalent trends, the global vaccines market is anticipated to be worth around USD 100 billion in 2025. Amidst the recent initiatives in this context, several viral vaccine media developers have established various partnerships for the clinical and commercial manufacturing of viral vaccines.

Vaccine manufacturing is a highly regulated and challenging process; specifically, the production of viral components or whole viruses further adds to the complexity. Additionally, it is paramount for vaccine cultures to be devoid of any contamination and be highly effective. In order to mitigate the aforementioned challenges, pharma and biotech companies are gradually adopting viral vaccine cell culture media for vaccines manufacturing. As a matter of fact, the recent surge in vaccine demand amidst the COVID-19 pandemic has served to facilitate a strong case for organizations to opt such media for the development and manufacturing of large quantities of vaccines. In fact, players engaged in this domain have shifted their focus towards serum free and animal component free media to carry out vaccine manufacturing owing to the various benefits offered by these media formulations, including low contamination rate. Given that the demand for viral vaccine is indubitably rising, the corresponding opportunity for viral vaccine cell culture media is expected to witness steady growth, over the next decade.

Scope of the Report

The "Viral Vaccine Cell Culture Media Market Distribution by Type of Cell Culture (Adherent and Suspension), Type of Media (Animal Component Free, Protein Free and Serum Free), Scale of Operation (Clinical Operations and Commercial Operations), Type of End-User (Industry Players and Non-Industry Players), and Key Geographical Regions (North America, Europe, Asia-Pacific, and Rest of the World): Industry Trends and Global Forecasts, 2022-2035" report features an extensive study of the current market landscape and the likely future potential of the viral vaccine cell culture market, over the next decade. The study also features an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this field. Amongst other elements, the report features:

  • A detailed overview of the overall market landscape of players engaged in the development of viral vaccine cell culture media, along with the information on their year of establishment, company size, location of headquarters. Further, it highlights a detailed assessment of the overall market landscape of over 80 viral vaccine cell culture media, based on several relevant parameters, such as type of vaccine (protein subunit, viral vector, whole virus) , type of cell culture (adherent and suspension) , type of cell culture media (serum free, animal component free, protein free) , purpose of media (Vero cell lines, human embryonic kidney (HEK) cell lines, Madin-Darby canine kidney (MDCK) cell lines, baby hamster kidney (BHK) cell lines, Madin-Darby bovine kidney (MDBK) cell lines, other cell lines) , media formulation (liquid and powder) , and application area (research use and manufacturing) .
  • Elaborate profiles of prominent players (shortlisted based on number of products being offered) engaged in the development of viral vaccine cell culture media. Each company profile features a brief overview of the company, along with information on its year of establishment, number of employees, location of headquarters, key executives, financial details / information (if available), product portfolio, recent developments and an informed future outlook.
  • An analysis of the recent developments and initiatives within the viral vaccine cell culture media industry, highlighting information on several partnerships and collaborations and expansion initiatives that have taken place in this domain, during the period 2015-2021.
  • An in-depth analysis of more than 130 vaccine developers and 50 vaccine contract manufacturers that are likely to partner with viral vaccine cell culture media providers. These players have been shortlisted based on several relevant parameters, such as developer strength (which takes into account a company's size and its experience in this field) , pipeline strength and maturity (based on the number of pipeline drugs and affiliated stage of development) and availability of other vaccine development and manufacturing related capabilities.
  • An in-depth product competitiveness analysis of viral vaccine cell culture media based on supplier power (in terms of expertise of the developer) and key product-related specifications (such as type of media, purpose of media, application area, type of vaccine, media formulation) .
  • An elaborative brand positioning analysis of the leading industry players (shortlisted on the basis of year of establishment and company size) , highlighting the current perceptions regarding their proprietary brands across viral vaccine cell culture media.
  • Insightful patent analysis presenting an overview of how the industry is evolving from the R&D perspective. For this analysis, we considered over 3400 patents that have been filed / granted for viral vaccine cell culture media, between 2015 and 2021 (till November), highlighting key trends associated with these patents, across type of patents, publication year, issuing authorities involved, emerging focus area, patent age, CPC symbols, leading patent assignees (in terms of number of patents granted / filed) , patent characteristics and geography. It also includes a detailed patent benchmarking and an insightful valuation analysis.
  • An informed estimate of the annual demand for viral vaccine cell culture media (in terms of volume of media required for total number of cells), based on key geographical regions.

One of the key objectives of this report was to evaluate the current opportunity and the future potential associated with the viral vaccine cell culture media market, over the coming decade. We have developed an informed estimate on the likely evolution of the market in the short to mid-term and long term, for the period 2022-2035. Additionally, the report features the likely distribution of the current and forecasted opportunity across [A] type of cell culture (adherent and suspension) [B] type of cell culture media (animal component free, protein free and serum free), [C] scale of operation (clinical operations and commercial operations), [D] type of end-user (industry players and non-industry players), and [E] key geographical regions (North America, Europe, Asia-Pacific, and Rest of the World). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered:

  • Who are the key players engaged in the development of viral vaccine cell culture media?
  • Which type of cell culture is most commonly offered by viral vaccine cell culture media developers?
  • What type of partnership models are commonly adopted by stakeholders engaged in this industry?
  • What is the relative competitiveness of different viral vaccine cell culture media?
  • Who are the most likely partners for vaccine cell culture media developers?
  • What are the key challenges currently faced by stakeholders in this industry?
  • What are the anticipated future trends related to viral vaccine cell culture media developers?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Chapter Outlines

Chapter 2 is an executive summary of key insights captured in our research. It offers a high-level view on the current state of viral vaccine cell culture media market and its likely evolution in the mid to long term.

Chapter 3 provides a general introduction to vaccine cell culture media. It further includes a detailed discussion on the vaccine components, historical evolution and development of viral vaccines, along with information on the types of viral vaccine, cell culture and cell culture media. Furthermore, it provides a brief overview of the advantages offered by cell culture media and their key limitations.

Chapter 4 provides a detailed overview of the overall market landscape of players engaged in the development of viral vaccine cell culture media, along with the information on their year of establishment, company size, location of headquarters. Further, it highlights a detailed assessment of the overall market landscape of over 80 viral vaccine cell culture media, based on several relevant parameters, such as type of vaccine (protein subunit, viral vector, whole virus) , type of cell culture (adherent and suspension) , type of cell culture media (serum free, animal component free, protein free) , purpose of media (Vero cell lines, HEK cell lines, Madin-Darby canine kidney (MDCK) cell lines, baby hamster kidney (BHK) cell lines, Madin-Darby bovine kidney (MDBK) cell lines, other cell lines), media formulation (liquid and powder) , and application area (research use and manufacturing) .

Chapter 5 features elaborate profiles of prominent players (shortlisted based on number of products being offered) engaged in the development of viral vaccine cell culture media. Each company profile features a brief overview of the company, along with information on its year of establishment, number of employees, location of headquarters, key executives, financial details / information (if available), product portfolio, recent developments and an informed future outlook.

Chapter 6 provides detailed analysis of the recent developments and initiatives within the viral vaccine cell culture media industry, highlighting information on several partnerships and collaborations and expansion initiatives that have taken place in this domain, during the period 2015-2021.

Chapter 7 features an in-depth analysis of more than 130 vaccine developers and 50 vaccine contract manufacturers that are likely to partner with viral vaccine cell culture media providers. These players have been shortlisted based on several relevant parameters, such as developer strength (which takes into account a company's size and its experience in this field) , pipeline strength and maturity (based on the number of pipeline drugs and affiliated stage of development) and availability of other vaccine development and manufacturing related capabilities.

Chapter 8 features an in-depth product competitiveness analysis of viral vaccine cell culture media based on supplier power (in terms of expertise of the developer) and key product-related specifications (such as type of media, purpose of media, application area, type of vaccine, media formulation) .

Chapter 9 provides an elaborative brand positioning analysis of the leading industry players (shortlisted on the basis of year of establishment and company size) , highlighting the current perceptions regarding their proprietary brands across viral vaccine cell culture media.

Chapter 10 provides an in-depth patent analysis presenting an overview of how the industry is evolving from the R&D perspective. For this analysis, we considered over 2800 patents that have been filed / granted for viral vaccine cell culture media, between 2015 and 2021 (till November), highlighting key trends associated with these patents, across type of patents, publication year, issuing authorities involved, emerging focus area, patent age, CPC symbols, leading patent assignees (in terms of number of patents granted / filed) , patent characteristics and geography. It also includes a detailed patent benchmarking and an insightful valuation analysis.

Chapter 11 provides an informed estimate of the annual demand for viral vaccine cell culture media (in terms of volume of media required for total number of cells) , based on key geographical regions.

Chapter 12 features a detailed market forecast analysis, highlighting the likely evolution of the market in the short to mid-term and long term, for the period 2022-2035. Additionally, the report features the likely distribution of the current and forecasted opportunity across [A] type of cell culture (adherent and suspension) [B] type of cell culture media (animal component free, protein free and serum free), [C] scale of operation (clinical operations and commercial operations), [D] type of end-user (industry players and non-industry players), and [E] key geographical regions (North America, Europe, Asia-Pacific, and Rest of the World). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.

Chapter 13 is a summary of the entire report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 14 is a collection of interview transcripts of the discussion(s) that were held key stakeholders in the industry.

Chapter 15 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 16 is an appendix, which contains a list of companies and organizations mentioned in this report.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Key Questions Answered
  • 1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

  • 2.1. Chapter Overview

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Introduction to Viral Vaccine
    • 3.2.1. Vaccine Components
    • 3.2.2. Historical Evolution
    • 3.2.3. Viral Vaccine Development
  • 3.3. Type of Viral Vaccine
    • 3.3.1. Whole Virus
    • 3.3.2. Protein Subunit
    • 3.3.3. Nucleic Acid
    • 3.3.4 Viral Vector
  • 3.4. Type of Cell Culture
  • 3.5. Type of Cell Culture Media
  • 3.6. Advantages of Cell Culture Media
  • 3.7. Limitations Associated with Cell Culture Media
  • 3.8. Conclusion

4. MARKET LANDSCAPE

  • 4.1. Chapter Overview
  • 4.2. Viral Vaccine Cell Culture Media: Overall Market Landscape
    • 4.2.1. Analysis by Type of Vaccine
    • 4.2.2. Analysis by Type of Cell Culture
    • 4.2.3. Analysis by Type of Cell Culture Media
    • 4.2.4. Analysis by Type of Cell Culture and Media
    • 4.2.5. Analysis by Type of Cell Line
    • 4.2.6. Analysis by Type of Cell Culture Media and Type of Cell Line
    • 4.2.7. Analysis by Media Formulation
    • 4.2.8. Analysis by Application Area
  • 4.3. Viral Vaccine Cell Culture Media Developers: Market Landscape
    • 4.3.1. Analysis by Year of Establishment
    • 4.3.2. Analysis by Company Size
    • 4.3.3. Analysis by Location of Headquarters
    • 4.3.4. Analysis by Number of Products

5. COMPANY PROFILES

  • 5.1. Chapter Overview
  • 5.2. Players based in North America
    • 5.2.1. Creative Biolabs
      • 5.2.1.1. Company Overview
      • 5.2.1.2. Financial Information
      • 5.2.1.3. Product Portfolio
      • 5.2.1.4. Future Outlook
    • 5.2.2. Jianshun Biosciences
      • 5.2.2.1. Company Overview
      • 5.2.2.2. Financial Information
      • 5.2.2.3. Product Portfolio
      • 5.2.2.4. Future Outlook
    • 5.2.3. Thermo Fisher Scientific
      • 5.2.3.1. Company Overview
      • 5.2.3.2. Financial Information
      • 5.2.3.3. Product Portfolio
      • 5.2.3.4. Future Outlook
  • 5.3. Players based in Europe
    • 5.3.1. Merck
      • 5.3.1.1. Company Overview
      • 5.3.1.2. Financial Information
      • 5.3.1.3. Product Portfolio
      • 5.3.1.4. Future Outlook
    • 5.3.2. Sartorius
      • 5.3.2.1. Company Overview
      • 5.3.2.2. Financial Information
      • 5.3.2.3. Product Portfolio
      • 5.3.2.4. Future Outlook
    • 5.3.3. Xell
      • 5.3.3.1. Company Overview
      • 5.3.3.2. Financial Information
      • 5.3.3.3. Product Portfolio
      • 5.3.3.4. Future Outlook
  • 5.4. Players based in Asia-Pacific
    • 5.4.1. ATZ labs
      • 5.4.1.1. Company Overview
      • 5.4.1.2. Financial Information
      • 5.4.1.3. Product Portfolio
      • 5.4.1.4. Future Outlook
    • 5.4.2. OPM Biosciences
      • 5.4.2.1. Company Overview
      • 5.4.2.2. Financial Information
      • 5.4.2.3. Product Portfolio
      • 5.4.2.4. Future Outlook

6. RECENT DEVELOPMENTS AND INITIATIVES

  • 6.1. Chapter Overview
  • 6.2. Partnership Models
  • 6.3. Viral Vaccine Cell Culture Media: Recent Partnerships and Collaborations
    • 6.3.1. Analysis by Year of Partnership
    • 6.3.2. Analysis by Type of Partnership
      • 6.3.2.1. Analysis by Year and Type of Partnership
      • 6.3.2.2. Analysis by Type of Partnership and Company Size
    • 6.3.3. Most Active Players: Analysis by Number of Partnerships
    • 6.3.4. Regional Analysis
      • 6.3.4.1. Intercontinental and Intracontinental Agreements
    • 6.3.5. Cumulative Year-wise Trend of Merger / Acquisition
    • 6.3.6. Analysis by Type of Acquisition
    • 6.3.7. Analysis by Key Value Drivers
    • 6.3.8. Analysis by Year of Acquisition and Key Value Drivers
  • 6.4. Viral Vaccine Cell Culture Media: Recent Expansions

7. LIKELY PARTNER ANALYSIS

  • 7.1. Chapter Overview
  • 7.2. Scope and Methodology
  • 7.3. Potential Strategic Partners for Viral Vaccine Cell Culture Media Developers
    • 7.3.1. Likely Partner Opportunities in Preventive Vaccine Developers
    • 7.3.2. Likely Partner Opportunities in Therapeutic Vaccine Developers
    • 7.3.3. Likely Partner Opportunities in Vaccine Contract Manufacturers

8. PRODUCT COMPETITIVENESS ANALYSIS

  • 8.1. Chapter Overview
  • 8.2. Methodology
  • 8.3. Assumptions / Key Parameters
  • 8.4. Product Competitiveness: Adherent Cell Culture Media
  • 8.5. Product Competitiveness: Suspension Cell Culture Media

9. BRAND POSITIONING

  • 9.1. Chapter Overview
  • 9.2. Key Parameters and Methodology
  • 9.3. Brand Positioning Matrix: Cytiva
  • 9.4. Brand Positioning Matrix: FUJIFILM Wako Chemicals
  • 9.5. Brand Positioning Matrix: Lonza
  • 9.6. Brand Positioning Matrix: Merck
  • 9.7. Brand Positioning Matrix: Sartorius
  • 9.8. Brand Positioning Matrix: Thermo Fisher Scientific

10. PATENT ANALYSIS

  • 10.1. Chapter Overview
  • 10.2. Scope and Methodology
  • 10.3. Viral Vaccine Cell Culture Media: Patent Analysis
    • 10.3.1. Analysis by Type of Patent
    • 10.3.2. Analysis by Publication Year
    • 10.3.3. Analysis by Granted Patents
    • 10.3.4. Year-wise Trend of Filed Patent Applications
    • 10.3.5. Analysis by Issuing Authority
    • 10.3.6. Analysis by Patent Focus
    • 10.3.7. Analysis by Patent Age
    • 10.3.8. Analysis by CPC Symbols
    • 10.3.9. Analysis by Type of Applicant
    • 10.3.10. Leading Players: Analysis by Number of Patents
  • 10.4. Viral Vaccine Cell Culture Media: Patent Benchmarking Analysis
    • 10.4.1. Analysis by Patent Characteristics
    • 10.4.2. Analysis by Geography
  • 10.5. Viral Vaccine Cell Culture Media: Patent Valuation Analysis

11. DEMAND ANALYSIS

  • 11.1. Chapter Overview
  • 11.2. Scope and Methodology
  • 11.3. Global Demand for Viral Vaccine
    • 11.3.1. Global Demand for Scale of Operation
      • 11.3.1.1. Clinical Demand for Viral Vaccine
      • 11.3.1.2. Commercial Demand for Viral Vaccine
    • 11.4.1. Geographical Analysis of Demand
      • 11.4.1.1. Overall Demand in North America for Viral Vaccine
      • 11.4.1.2. Overall Demand in Europe for Viral Vaccine
      • 11.4.1.3. Overall Demand in Asia-Pacific and Rest of the World for Viral Vaccine

12. MARKET FORECAST

  • 12.1. Chapter Overview
  • 12.2. Forecast Methodology and Key Assumptions
  • 12.3. Global Viral Vaccine Cell Culture Media Market, 2022-2035
  • 12.4. Viral Vaccine Cell Culture Media Market: Analysis by Type of Cell Culture, 2022-2035
    • 12.4.1. Viral Vaccine Cell Culture Media Market for Adherent Cell Culture, 2022-2035
    • 12.4.2. Viral Vaccine Cell Culture Media Market for Suspension Cell Culture, 2022-2035
  • 12.5. Viral Vaccine Cell Culture Media Market: Analysis by Type of Cell Culture Media, 2022-2035
    • 12.5.1. Viral Vaccine Cell Culture Media Market for Animal Component Free Media, 2022-2035
    • 12.5.2. Viral Vaccine Cell Culture Media Market for Protein Free Media, 2022-2035
    • 12.5.3. Viral Vaccine Cell Culture Media Market for Serum Free Media, 2022-2035
  • 12.6. Viral Vaccine Cell Culture Media Market: Analysis by Scale of Operation, 2022-2035
    • 12.6.1. Viral Vaccine Cell Culture Media Market for Clinical Operations, 2022-2035
    • 12.6.2. Viral Vaccine Cell Culture Media Market for Commercial Operations, 2022-2035
  • 12.7. Viral Vaccine Cell Culture Media Market: Analysis by Type of End-User, 2022-2035
    • 12.7.1. Viral Vaccine Cell Culture Media Market for Industry Players, 2022-2035
    • 12.7.2. Viral Vaccine Cell Culture Media Market for Non-Industry Players, 2022-2035
  • 12.8. Viral Vaccine Cell Culture Media Market: Analysis by Geography, 2022-2035
    • 12.8.1. Viral Vaccine Cell Culture Media Market in North America, 2022-2035
    • 12.8.2. Viral Vaccine Cell Culture Media Market in Europe, 2022-2035
    • 12.8.3. Viral Vaccine Cell Culture Media Market in Asia-Pacific, 2022-2035
    • 12.8.4. Viral Vaccine Cell Culture Media Market in Rest of the World, 2022-2035

13. CONCLUSION

  • 13.1. Chapter Overview

14. INTERVIEW TRANSCRIPT(S)

15. APPENDIX I: TABULATED DATA

16. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

  • Figure 2.1 Executive Summary: Overall Market Landscape
  • Figure 2.2 Executive Summary: Recent Developments and Initiatives
  • Figure 2.3 Executive Summary: Patent Analysis
  • Figure 2.4 Executive Summary: Demand Analysis
  • Figure 2.5 Executive Summary: Market Forecast
  • Figure 3.1 Components of Vaccine
  • Figure 3.2 Stages of Viral Vaccine Development
  • Figure 3.3 Types of Viral Vaccines
  • Figure 3.4 Types of Cell Culture Media
  • Figure 4.1 Viral Vaccine Cell Culture Media: Distribution by Types of Vaccines
  • Figure 4.2 Viral Vaccine Cell Culture Media: Distribution by Types of Cell Culture
  • Figure 4.3 Viral Vaccine Cell Culture Media: Distribution by Types of Cell Culture Media
  • Figure 4.4 Viral Vaccine Cell Culture Media: Distribution by Types of Cell Culture and Media
  • Figure 4.5 Viral Vaccine Cell Culture Media: Distribution by Type of Cell Line
  • Figure 4.6 Viral Vaccine Cell Culture Media: Distribution by Types of Cell Culture Media and Type of Cell Line
  • Figure 4.7 Viral Vaccine Cell Culture Media: Distribution by Application Area
  • Figure 4.8 Viral Vaccine Cell Culture Media Developers: Distribution by Year of Establishment
  • Figure 4.9 Viral Vaccine Cell Culture Media Developers: Distribution by Company Size
  • Figure 4.10 Viral Vaccine Cell Culture Media Developers: Distribution by Location of Headquarters
  • Figure 4.11 Most Active Players: Distribution by Number of Products
  • Figure 5.1 Thermo Fisher Scientific: Annual Revenues, 2016 - 9M 2021 (USD Billion)
  • Figure 5.2 Merck: Annual Revenues, 2016 - 9M 2021 (EUR Billion)
  • Figure 5.3 Sartorius: Annual Revenues, 2016 - 9M 2021 (EUR Million)
  • Figure 6.1 Partnerships and Collaborations: Distribution by Year of Partnership
  • Figure 6.2 Partnerships and Collaborations: Distribution by Types of Partnership
  • Figure 6.3 Partnerships and Collaborations: Distribution by Year and Types of Partnership
  • Figure 6.4 Partnerships and Collaborations: Distribution by Types of Partnership and Company Size
  • Figure 6.5 Most Active Players: Distribution by Number of Partnerships
  • Figure 6.6 Partnerships and Collaborations: Regional Distribution
  • Figure 6.7 Partnerships and Collaborations: Country-wise Distribution
  • Figure 6.8 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
  • Figure 9.1 Brand Positioning Analysis: Competitive Advantage of Key Industrial Players
  • Figure 9.2 Brand Positioning Analysis: Reasons to Believe
  • Figure 9.3 Brand Positioning Matrix: Cytiva
  • Figure 9.4 Brand Positioning Matrix: FUJIFILM Wako Chemicals
  • Figure 9.5 Brand Positioning Matrix: Lonza
  • Figure 9.6 Brand Positioning Matrix: Merck
  • Figure 9.7 Brand Positioning Matrix: Sartorius
  • Figure 9.8 Brand Positioning Matrix: Thermo Fisher Scientific
  • Figure 10.1 Patent Analysis: Distribution by Type of Patent
  • Figure 10.2 Patent Analysis: Cumulative Distribution by Publication Year, 2015-2021
  • Figure 10.3 Patent Analysis: Distribution of Granted Patents by Publication Year, 2015-2021
  • Figure 10.4 Patent Analysis: Distribution of Filed Patents by Publication Year, 2015-2021
  • Figure 10.5 Patent Analysis: Distribution by Issuing Authority
  • Figure 10.6 Patent Analysis: Distribution by Patent Focus
  • Figure 10.7 Patent Analysis: Distribution by Patent Age
  • Figure 10.8 Patent Analysis: Distribution by CPC Symbols
  • Figure 10.9 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant (2015 - 2021)
  • Figure 10.10 Leading Players Assignees: Distribution by Number of Patents
  • Figure 10.11 Patent Analysis (Top 10 CPC Symbols): Benchmarking by Leading Players
  • Figure 10.12 Patent Analysis: Benchmarking by International Patents
  • Figure 10.13 Patent Valuation Analysis
  • Figure 11.1 Clinical Demand for Viral Vaccine, 2022-2035 (Million Liters)
  • Figure 11.2 Commercial Demand for Viral Vaccine, 2022-2035 (Million Liters)
  • Figure 11.3 Global Demand for Viral Vaccine in North America, 2022-2035 (Million Liters)
  • Figure 11.4 Global Demand for Viral Vaccine in Europe, 2022-2035 (Million Liters)
  • Figure 11.5 Global Demand for Viral Vaccine in Asia-Pacific and Rest of the World, 2022-2035 (Million Liters)
  • Figure 12.1 Global Viral Vaccine Cell Culture Media Market, 2022-2035 (USD Billion)
  • Figure 12.2 Viral Vaccine Cell Culture Media Market: Distribution by Types of Cell Culture, 2022 and 2032
  • Figure 12.3 Viral Vaccine Cell Culture Media Market for Adherent Cell Culture, 2022-2035 (USD Million)
  • Figure 12.4 Viral Vaccine Cell Culture Media Market for Suspension Cell Culture, 2022-2035 (USD Million)
  • Figure 12.5 Viral Vaccine Cell Culture Media Market: Distribution by Types of Cell Culture Media, 2022 and 2032
  • Figure 12.6 Viral Vaccine Cell Culture Media Market for Animal Component Free Media, 2022-2035 (USD Million)
  • Figure 12.7 Viral Vaccine Cell Culture Media Market for Protein Free Media, 2022-2035 (USD Million)
  • Figure 12.8 Viral Vaccine Cell Culture Media Market for Serum Free Media, 2022-2035 (USD Million)
  • Figure 12.9 Viral Vaccine Cell Culture Media Market: Distribution by Scale of Operation, 2022 and 2032
  • Figure 12.10 Viral Vaccine Cell Culture Media Market for Clinical Operations, 2022-2035 (USD Million)
  • Figure 12.11 Viral Vaccine Cell Culture Media Market for Commercial Operations, 2022-2035 (USD Million)
  • Figure 12.12 Viral Vaccine Cell Culture Media Market: Distribution by Types of End-User, 2022 and 2032
  • Figure 12.13 Viral Vaccine Cell Culture Media Market for Industry Players, 2022-2035 (USD Million)
  • Figure 12.14 Viral Vaccine Cell Culture Media Market for Non-Industry Players, 2022-2035 (USD Million)
  • Figure 12.15 Viral Vaccine Cell Culture Media Market: Distribution by Geography, 2022 and 2032
  • Figure 12.16 Viral Vaccine Cell Culture Media Market in North America, 2022-2035 (USD Million)
  • Figure 12.17 Viral Vaccine Cell Culture Media Market in Europe, 2022-2035 (USD Million)
  • Figure 12.18 Viral Vaccine Cell Culture Media Market in Asia-Pacific, 2022-2035 (USD Million)
  • Figure 12.19 Viral Vaccine Cell Culture Media Market in Rest of the World, 2022-2035 (USD Million)
  • Figure 13.1 Concluding Remarks: Current Market Landscape
  • Figure 13.2 Concluding Remarks: Recent Developments and Initiatives
  • Figure 13.3 Concluding Remarks: Patent Analysis
  • Figure 13.4 Concluding Remarks: Demand Analysis
  • Figure 13.5 Concluding Remarks: Market Sizing and Opportunity Analysis

List Of Tables

  • Table 3.1 Comparison between Adherent and Suspension Cell Culture
  • Table 4.1 Viral Vaccine Cell Culture Media: Information on Developer, Types of Vaccine, and Virus Cultured
  • Table 4.2 Viral Vaccine Cell Culture Media: Information on Types of Cell Culture and Types of Cell Culture Media
  • Table 4.3 Viral Vaccine Cell Culture Media: Information on Type of Cell Line
  • Table 4.4 Viral Vaccine Cell Culture Media: Information on Media Formulation, Available Package Volume and Price
  • Table 4.5 Viral Vaccine Cell Culture Media: Information on Application Area, Accreditations Received, Types of End-User and Scale of Operation
  • Table 4.6 Viral Vaccine Cell Culture Media Developers: Information on Year of Establishment, Company Size and Location of Headquarters
  • Table 5.1 Creative Biolabs: Company Snapshot
  • Table 5.2 Creative Biolabs: Product Portfolio
  • Table 5.3 Jianshun Biosciences: Company Snapshot
  • Table 5.4 Jianshun Biosciences: Product Portfolio
  • Table 5.5 Thermo Fisher Scientific: Company Snapshot
  • Table 5.6 Thermo Fisher Scientific: Product Portfolio
  • Table 5.7 Merck: Company Snapshot
  • Table 5.8 Merck: Product Portfolio
  • Table 5.9 Merck: Recent Developments and Future Outlook
  • Table 5.10 Sartorius: Company Snapshot
  • Table 5.11 Sartorius: Product Portfolio
  • Table 5.12 Sartorius: Recent Developments and Future Outlook
  • Table 5.13 Xell: Company Snapshot
  • Table 5.14 Xell: Product Portfolio
  • Table 5.15 Xell: Recent Developments and Future Outlook
  • Table 5.16 ATZ labs: Company Snapshot
  • Table 5.17 ATZ labs: Product Portfolio
  • Table 5.18 OPM Biosciences: Company Snapshot
  • Table 5.19 OPM Biosciences: Product Portfolio
  • Table 6.1 Partnerships and Collaborations: List of Partnership, 2015-2021
  • Table 6.2 Viral Vaccine Cell Culture Media: List of Recent Expansions, 2015-2021
  • Table 7.1 Likely Partners for Preventive Vaccine Developers
  • Table 7.2 Likely Partners for Therapeutic Vaccine Developers
  • Table 7.3 Likely Partners for Vaccine Contract Manufacturers
  • Table 8.1 Product Competitiveness Analysis: Adherent Cell Culture Media
  • Table 8.2 Product Competitiveness Analysis: Suspension Cell Culture Media
  • Table 10.1 Patent Analysis: Distribution by CPC Symbols
  • Table 10.2 Patent Analysis: Most Popular CPC Symbols
  • Table 10.3 Patent Analysis: List of Top CPC Symbols
  • Table 10.4 Patent Analysis: Categorization based on Weighted Valuation Scores
  • Table 10.5 Leading Patents: Distribution by Number of Citations
  • Table 13.1 Conclusion: Overall Market Landscape
  • Table 13.2 Conclusion: Recent Developments and Initiatives
  • Table 13.3 Conclusion: Patent Analysis
  • Table 13.4 Conclusion: Demand Analysis
  • Table 13.5 Conclusion: Market Forecast
  • Table 15.1 Viral Vaccine Cell Culture Media: Distribution by Types of Vaccines
  • Table 15.2 Viral Vaccine Cell Culture Media: Distribution by Types of Cell Culture
  • Table 15.3 Viral Vaccine Cell Culture Media: Distribution by Types of Cell Culture Media
  • Table 15.4 Viral Vaccine Cell Culture Media: Distribution by Types of Cell Culture and Media
  • Table 15.5 Viral Vaccine Cell Culture Media: Distribution by Type of Cell Line
  • Table 15.6 Viral Vaccine Cell Culture Media: Distribution by Types of Cell Culture Media and Type of Cell Line
  • Table 15.7 Viral Vaccine Cell Culture Media: Distribution by Media Formulation
  • Table 15.8 Viral Vaccine Cell Culture Media: Distribution by Application Area
  • Table 15.9 Viral Vaccine Cell Culture Media Developers: Distribution by Year of Establishment
  • Table 15.10 Viral Vaccine Cell Culture Media Developers: Distribution by Company Size
  • Table 15.11 Viral Vaccine Cell Culture Media Developers: Distribution by Location of Headquarters
  • Table 15.12 Most Active Players: Distribution by Number of Products
  • Table 15.13 Thermo Fisher Scientific: Annual Revenues, 2016 -9M 2021 (USD Billion)
  • Table 15.14 Merck: Annual Revenues, 2016 -9M 2021 (EUR Billion)
  • Table 15.15 Sartorius: Annual Revenues, 2016 - 9M 2021 (EUR Million)
  • Table 15.16 Partnerships and Collaborations: Distribution by Year of Partnership
  • Table 15.17 Partnerships and Collaborations: Distribution by Types of Partnership
  • Table 15.18 Partnerships and Collaborations: Distribution by Year and Types of Partnership
  • Table 15.19 Partnerships and Collaborations: Distribution by Types of Partnership and Company Size
  • Table 15.20 Most Active Players: Distribution by Number of Partnerships
  • Table 15.21 Partnerships and Collaborations: Regional Distribution
  • Table 15.22 Partnerships and Collaborations: Country-wise Distribution
  • Table 15.23 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
  • Table 15.24 Patent Analysis: Distribution by Type of Patent
  • Table 15.25 Patent Analysis: Cumulative Distribution by Publication Year, 2015 - 2021
  • Table 15.26 Patent Analysis: Distribution of Granted Patents by Publication Year, 2015-2021
  • Table 15.27 Patent Analysis: Distribution of Filed Patents by Publication Year, 2015 - 2021
  • Table 15.28 Patent Analysis: Distribution by Issuing Authority
  • Table 15.29 Patent Analysis: Distribution by Patent Age
  • Table 15.30 Patent Analysis: Distribution by CPC Symbols
  • Table 15.31 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant (2015 - 2021)
  • Table 15.32 Leading Players Assignees: Distribution by Number of Patents
  • Table 15.33 Patent Analysis (Top 10 CPC Symbols): Benchmarking by Leading Players
  • Table 15.34 Patent Analysis: Benchmarking by International Patents
  • Table 15.35 Patent Valuation Analysis
  • Table 15.36 Clinical Demand for Viral Vaccine, 2022-2035 (Million Liters)
  • Table 15.37 Commercial Demand for Viral Vaccine, 2022-2035 (Million Liters)
  • Table 15.38 Global Demand for Viral Vaccine in North America, 2022-2035 (Million Liters)
  • Table 15.39 Global Demand for Viral Vaccine in Europe, 2022-2035 (Million Liters)
  • Table 15.40 Global Demand for Viral Vaccine in Asia-Pacific and Rest of the World, 2022-2035 (Million Liters)
  • Table 15.41 Global Viral Vaccine Cell Culture Media Market, 2022-2035 (USD Billion)
  • Table 15.42 Viral Vaccine Cell Culture Media Market: Distribution by Types of Cell Culture, 2022 and 2032
  • Table 15.43 Viral Vaccine Cell Culture Media Market for Adherent Cell Culture, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 15.44 Viral Vaccine Cell Culture Media Market for Suspension Cell Culture, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 15.45 Viral Vaccine Cell Culture Media Market: Distribution by Types of Cell Culture Media, 2022 and 2032
  • Table 15.46 Viral Vaccine Cell Culture Media Market for Animal Component Free Media, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 15.47 Viral Vaccine Cell Culture Media Market for Protein Free Media, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 15.48 Viral Vaccine Cell Culture Media Market for Serum Free Media, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 15.49 Viral Vaccine Cell Culture Media Market: Distribution by Scale of Operation, 2022 and 2032
  • Table 15.50 Viral Vaccine Cell Culture Media Market for Clinical Operations, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 15.51 Viral Vaccine Cell Culture Media Market for Commercial Operations, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 15.52 Viral Vaccine Cell Culture Media Market: Distribution by Types of End-User, 2022 and 2032
  • Table 15.53 Viral Vaccine Cell Culture Media Market for Industry Players, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 15.54 Viral Vaccine Cell Culture Media Market for Non-Industry Players, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 15.55 Viral Vaccine Cell Culture Media Market: Distribution by Geography, 2022 and 2032
  • Table 15.56 Viral Vaccine Cell Culture Media Market in North America, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 15.57 Viral Vaccine Cell Culture Media Market in Europe, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 15.58 Viral Vaccine Cell Culture Media Market in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 15.59 Viral Vaccine Cell Culture Media Market in Rest of the World, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)

List Of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

  • 1. 2BScientific
  • 2. Adimmune
  • 3. Aduro Biotech
  • 4. Advagene Biopharma
  • 5. Advanced Bioprocessing Business (A subsidiary of Thermo Fisher Scientific)
  • 6. Advanced BioScience Laboratories
  • 7. Advent
  • 8. AJ Biologics
  • 9. Albany Molecular Research
  • 10. Alopexx Vaccine
  • 11. Altimmune
  • 12. Amphera
  • 13. Anhui Zhifei Longcom Biologic Pharmacy
  • 14. Applied Biosystems
  • 15. Argos Therapeutics
  • 16. Astellas Pharma
  • 17. Asterias Biotherapeutics
  • 18. ATZ labs
  • 19. Auro Vaccines
  • 20. Aurora Biopharma
  • 21. AVAX Technologies
  • 22. Avid Bioservices
  • 23. AVIR Green Hills Biotechnology
  • 24. Batavia Biosciences
  • 25. Bavarian Nordic
  • 26. BD Biosciences
  • 27. Beijing Minhai Biotechnology
  • 28. Beijing Zhifei Lvzhu Biopharmaceutical
  • 29. Bharat Biotech
  • 30. Bielefeld University
  • 31. Bio Farma
  • 32. BioCell
  • 33. BioConnection
  • 34. Biofabri
  • 35. Biological E
  • 36. Biological Industries
  • 37. BioMARC
  • 38. BioReliance
  • 39. BlueWillow Biologics
  • 40. Boehringer Ingelheim
  • 41. Boryung Pharmaceutical
  • 42. BravoVax
  • 43. Bryllan
  • 44. CanSino Biologics
  • 45. Capricorn Scientific
  • 46. Catalent Biologics
  • 47. Cellca (Acquired by Sartorius)
  • 48. CellGenix
  • 49. CEVEC Pharmaceuticals
  • 50. Charles River Laboratories
  • 51. Chengdu Zenmindes Biotechnology
  • 52. CiMaas
  • 53. CJ HealthCare
  • 54. Cobra Biologics
  • 55. Codagenix
  • 56. Commonwealth Serum Laboratories (CSL)
  • 57. Creative Biolabs
  • 58. Curevo Vaccine
  • 59. Cytiva
  • 60. CyTuVax
  • 61. Daiichi Sankyo
  • 62. DanDrit Biotech
  • 63. DCPrime
  • 64. Dendreon
  • 65. Elios Therapeutics
  • 66. Emergent BioSolutions
  • 67. Fisher Scientific (Acquired by Thermo Fisher Scientific)
  • 68. FluGen
  • 69. FUJIFILM Wako Pure Chemicals
  • 70. GC Pharma
  • 71. GeneOne Life Science
  • 72. GlaxoSmithKline
  • 73. Gradalis
  • 74. HALIX
  • 75. Heat Biologics
  • 76. Hilleman Laboratories
  • 77. Hookipa Biotech
  • 78. Icahn School of Medicine at Mount Sinai
  • 79. IDT Biologika
  • 80. ILiAD Biotechnologies
  • 81. Immunicum
  • 82. ImmunoCellular Therapeutics
  • 83. Immutep
  • 84. Indian Immunologicals
  • 85. Inovio Pharmaceuticals
  • 86. Institut National de la Santé et de la Recherche Médicale (INSERM)
  • 87. Insud Pharma
  • 88. Intermountain Life Sciences
  • 89. Intervet
  • 90. InVitria
  • 91. Invitrogen
  • 92. Irvine Scientific Sales (Acquired by FUJIFILM)
  • 93. IS JAPAN (Acquired by FUJIFILM)
  • 94. Janssen Pharmaceuticals
  • 95. Jianshun Biosciences
  • 96. JN International Medical
  • 97. JW CreaGene
  • 98. Kansas State University
  • 99. KBI Biopharma
  • 100. Kiromic
  • 101. Leland Stanford Junior University
  • 102. LG Chem
  • 103. LimmaTech Biologics
  • 104. Lonza
  • 105. Luina Bio
  • 106. Massachusetts Institute of Technology
  • 107. MassBiologics
  • 108. Medicago
  • 109. Medigen Vaccine Biologics
  • 110. Medigene
  • 111. Meissa Vaccines
  • 112. Merck
  • 113. Meridian Life Science
  • 114. MilliporeSigma
  • 115. MinervaX
  • 116. Moderna
  • 117. MolecuVax
  • 118. Northwest Biotherapeutics
  • 119. Nova Immunotherapeutics
  • 120. Novartis
  • 121. Novasep
  • 122. Novavax
  • 123. NPO Petrovax Pharm
  • 124. Ology Bioservices
  • 125. Oncobiomed
  • 126. OPM Biosciences
  • 127. Osivax
  • 128. Oxford Biomedica
  • 129. Pall Corporation
  • 130. Panacea Biotec
  • 131. Patheon Viral Vector Services
  • 132. PDC*line Pharma
  • 133. Pfizer
  • 134. Premas Biotech
  • 135. Prestige BioPharma
  • 136. ProBioGen
  • 137. Regeneus
  • 138. Research Institute at Nationwide Children's Hospital
  • 139. Sanaria
  • 140. Sanofi Pasteur
  • 141. Saronic Biotechnology
  • 142. Sartorius
  • 143. Scandinavian Biopharma
  • 144. Seqirus
  • 145. Serum Institute of India
  • 146. Shanghai Bovax Biotechnology
  • 147. Shenzhen Hornetcorn Biotechnology
  • 148. Shenzhen Kangtai Biological Products
  • 149. Sigma-Aldrich
  • 150. SK Bioscience
  • 151. SOTIO
  • 152. Symbiosis Pharmaceutical Services
  • 153. Takeda
  • 154. TapImmune
  • 155. Tella
  • 156. Tessa Therapeutics
  • 157. TeutoCell
  • 158. Themis Bioscience
  • 159. Thermo Electron
  • 160. Thermo Fisher Scientific
  • 161. Thousand Oaks Biopharmaceuticals
  • 162. TNCbio
  • 163. Unity Lab Services
  • 164. University of California
  • 165. University of Pennsylvania
  • 166. University of Texas
  • 167. USHEALTH
  • 168. Vaccinogen
  • 169. Vaccitech
  • 170. Valneva
  • 171. Vaxart
  • 172. Vaxine
  • 173. Vibalogics
  • 174. Waisman Biomanufacturing
  • 175. WuXi Biologics
  • 176. Xell
  • 177. XEME Biopharma